Apparent China Study Failure May Not Spell End For Remdesivir COVID-19 Role

Antiviral‘s Role In Severe Patients Is Bigger Question

 
• By Brian Yang

Apparently disappointing results from the world’s first randomized study for Gilead's remdesivir in COVID-19 have some wondering about whether antiviral can still play a decisive role in some patients with COVID-19.

Corona patient
RESULTS FROM REMDESIVIR CHINA STUDY SHOWS NO SIGNIFICANT IMPROVE IN COVID-19 MORTALITY • Source: Shutterstock

More from China

More from Focus On Asia